1. Home
  2. SNEX vs KOD Comparison

SNEX vs KOD Comparison

Compare SNEX & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StoneX Group Inc.

SNEX

StoneX Group Inc.

N/A

Current Price

$39.44

Market Cap

6.8B

Sector

Finance

ML Signal

N/A

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

N/A

Current Price

$97.84

Market Cap

6.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNEX
KOD
Founded
1924
2009
Country
United States
United States
Employees
5400
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.2B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
SNEX
KOD
Price
$39.44
$97.84
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
★ $133.28
$130.17
AVG Volume (30 Days)
722.8K
★ 737.6K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 3.49
N/A
Revenue
★ $132,378,200,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.67
★ N/A
Revenue Growth
★ 32.53
N/A
52 Week Low
$52.26
$19.25
52 Week High
$141.99
$112.31

Technical Indicators

Market Signals
Indicator
SNEX
KOD
Relative Strength Index (RSI) 18.72 52.43
Support Level N/A $90.50
Resistance Level $70.35 $103.67
Average True Range (ATR) 2.56 6.74
MACD -0.73 -1.78
Stochastic Oscillator 2.71 32.28

Price Performance

Historical Comparison
SNEX
KOD

About SNEX StoneX Group Inc.

StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: